PL377530A1 - Pochodne imidazoli mające powinowactwo do receptorów alfa 2 - Google Patents

Pochodne imidazoli mające powinowactwo do receptorów alfa 2

Info

Publication number
PL377530A1
PL377530A1 PL377530A PL37753003A PL377530A1 PL 377530 A1 PL377530 A1 PL 377530A1 PL 377530 A PL377530 A PL 377530A PL 37753003 A PL37753003 A PL 37753003A PL 377530 A1 PL377530 A1 PL 377530A1
Authority
PL
Poland
Prior art keywords
unsubstituted
substituted
affinity
alpha
prodrug forms
Prior art date
Application number
PL377530A
Other languages
English (en)
Other versions
PL216530B1 (pl
Inventor
Tomi Järvinen
Riku Niemi
Juhani Huuskonen
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of PL377530A1 publication Critical patent/PL377530A1/pl
Publication of PL216530B1 publication Critical patent/PL216530B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL377530A 2002-12-05 2003-12-05 Estry alkilowe 4-(6-hydroksyindan-1-ylometylo)-1H-imidazolu, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne PL216530B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20022159A FI20022159A0 (fi) 2002-12-05 2002-12-05 Uusia farmaseuttisia yhdisteitä

Publications (2)

Publication Number Publication Date
PL377530A1 true PL377530A1 (pl) 2006-02-06
PL216530B1 PL216530B1 (pl) 2014-04-30

Family

ID=8565048

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377530A PL216530B1 (pl) 2002-12-05 2003-12-05 Estry alkilowe 4-(6-hydroksyindan-1-ylometylo)-1H-imidazolu, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne

Country Status (27)

Country Link
US (1) US7759496B2 (pl)
EP (1) EP1572198B1 (pl)
JP (1) JP4667042B2 (pl)
KR (1) KR20050114603A (pl)
CN (1) CN100560070C (pl)
AT (1) ATE323484T1 (pl)
BR (1) BR0317024A (pl)
CA (1) CA2508335C (pl)
CY (1) CY1105699T1 (pl)
DE (1) DE60304741T2 (pl)
DK (1) DK1572198T3 (pl)
EA (1) EA008251B1 (pl)
ES (1) ES2262031T3 (pl)
FI (1) FI20022159A0 (pl)
HR (1) HRP20050617B1 (pl)
IL (1) IL168882A (pl)
IS (1) IS2282B (pl)
ME (1) ME00521B (pl)
MX (1) MXPA05005963A (pl)
NO (1) NO330392B1 (pl)
NZ (1) NZ540466A (pl)
PL (1) PL216530B1 (pl)
PT (1) PT1572198E (pl)
RS (1) RS52571B (pl)
SI (1) SI1572198T1 (pl)
WO (1) WO2004050635A2 (pl)
ZA (1) ZA200504533B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1934203B1 (en) 2005-08-25 2010-08-18 Schering Corporation 3,4-dihydro-2H-benzo[1,4]oxazine and 3,4-dihydro-2H-benzo[1,4]thiazine COMPOUNDS AS ALPHA2C ADRENORECEPTOR AGONISTS
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
DK1117399T3 (da) 1998-09-28 2005-03-29 Orion Corp Anvendelse af 3-(1H-imidazol-4-ylmethyl)indan-5-ol til fremstilling af et lægemiddel til intraspinal, intrathekal eller epidural indgivelse
AU778522B2 (en) 1999-10-29 2004-12-09 Orion Corporation Treatment or prevention of hypotension and shock
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use

Also Published As

Publication number Publication date
ZA200504533B (en) 2006-03-29
RS52571B (sr) 2013-04-30
JP4667042B2 (ja) 2011-04-06
IS2282B (is) 2007-09-15
MXPA05005963A (es) 2005-08-18
AU2003302622A1 (en) 2004-06-23
FI20022159A0 (fi) 2002-12-05
PT1572198E (pt) 2006-08-31
WO2004050635A2 (en) 2004-06-17
EP1572198A2 (en) 2005-09-14
DK1572198T3 (da) 2006-07-03
IL168882A (en) 2010-05-31
KR20050114603A (ko) 2005-12-06
US7759496B2 (en) 2010-07-20
BR0317024A (pt) 2005-10-25
EP1572198B1 (en) 2006-04-19
DE60304741D1 (de) 2006-05-24
PL216530B1 (pl) 2014-04-30
HRP20050617A2 (en) 2005-10-31
DE60304741T2 (de) 2007-04-12
CY1105699T1 (el) 2010-12-22
NO330392B1 (no) 2011-04-04
NZ540466A (en) 2008-04-30
CA2508335C (en) 2011-09-13
ME00521B (me) 2011-10-10
ATE323484T1 (de) 2006-05-15
EA200500922A1 (ru) 2005-12-29
SI1572198T1 (sl) 2006-08-31
EA008251B1 (ru) 2007-04-27
CN100560070C (zh) 2009-11-18
NO20053302L (no) 2005-07-05
RS20050428A (sr) 2007-08-03
IS7911A (is) 2005-06-23
JP2006509780A (ja) 2006-03-23
HRP20050617B1 (hr) 2013-07-31
ES2262031T3 (es) 2006-11-16
WO2004050635A3 (en) 2004-09-02
NO20053302D0 (no) 2005-07-05
CA2508335A1 (en) 2004-06-17
CN1735409A (zh) 2006-02-15
US20060178417A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
ATE556058T1 (de) 1-(2h)-isochinolonderivat
AU2001235844A1 (en) Imidazol-2-carboxamide derivatives as raf kinase inhibitors
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
EA200601235A1 (ru) Производные тиазола
HUT71551A (en) Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives, process for producing them, and pharmaceutical compositions containing them
IL161559A0 (en) Dibenzylamine derivatives and pharmaceutical compositions containing the same
WO2002000650A3 (en) Novel compounds possessing antibacterial, antifungal or antitumor activity
AU2002211216A1 (en) Substituted aminopropoxyaryl derivatives useful as agonists for lxr
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
MXPA05003193A (es) Compuesto de adenina novedoso y uso del mismo.
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
CA2432578A1 (en) Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
IL156873A0 (en) Pharmaceutically active piperidine derivatives
DK0784054T3 (da) 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
DE60105610D1 (en) Pyrazinonderivate
HRP20050617A2 (en) Imidazol derivatives having affinity for alpha 2 receptors activity
WO2004091627A3 (en) Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
GC0000218A (en) New imidazole derivatives
AU2002244985A1 (en) Thiazolidinedione derivatives and pharmaceutical composition comprising the same
EP1142868A4 (en) AMIDE DERIVATIVES
EP1197211A4 (en) CANCER PREVENTION AND TREATMENT ACTIVE INGREDIENTS
EP1151993A4 (en) CYCLIC AMINE DERIVATIVES AND THEIR APPLICATIONS